Home / Current Issue / Paper 1711003
Community-Based Strategies for Reducing Drug Misuse: Evidence from Pharmacist-Led Interventions
Subject area: Biological & Medical Sciences · Area of research: Public Health and Pharmacology
Abstract
Drug misuse represents a persistent public health challenge requiring innovative community-based interventions that leverage healthcare professionals'expertise and accessibility. This comprehensive analysis examines the effectiveness of pharmacist-led interventions in reducing drug misuse within community settings, drawing from evidence collected through 2019. The study synthesizes findings from multiple intervention models, including medication therapy management programs, prescription drug monitoring initiatives, and community education campaigns facilitated by pharmacists across diverse geographic and demographic contexts. Pharmacists occupy a unique position within healthcare delivery systems, serving as highly accessible healthcare professionals who maintain regular contact with patients through prescription dispensing and medication counseling services. This accessibility, combined with specialized pharmaceutical knowledge and established community trust, positions pharmacists as ideal facilitators of drug misuse prevention and intervention programs. The evidence demonstrates that pharmacist-led interventions effectively reduce inappropriate medication use, improve medication adherence, and enhance patient understanding of proper medication management practices. Community-based strategies examined include collaborative care models where pharmacists work directly with physicians, social workers, and community organizations to identify at-risk individuals and provide targeted interventions. These programs have shown particular success in addressing prescription opioid misuse, polypharmacy in elderly populations, and medication adherence challenges among chronic disease patients. The interventions typically incorporate multiple components including individual patient counseling, group education sessions, prescription monitoring and review, and referral coordination with specialized treatment services. The methodology employed systematic review approaches to analyze intervention outcomes across various community settings, examining both quantitative measures such as prescription patterns and medication adherence rates, and qualitative indicators including patient satisfaction and community engagement levels. Results consistently demonstrate significant improvements in appropriate medication use, reduced emergency department visits related to medication errors, and enhanced patient knowledge regarding medication safety and proper use practices. Economic analyses reveal that pharmacist-led interventions provide substantial cost savings to healthcare systems through reduced hospitalizations, prevented adverse drug events, and improved medication adherence leading to better health outcomes. The interventions particularly demonstrate value in underserved communities where access to traditional healthcare services may be limited but pharmacy services remain readily available. Implementation challenges identified include workforce training requirements, sustainable funding mechanisms, and integration with existing healthcare delivery systems. However, successful programs demonstrate that these challenges can be effectively addressed through strategic planning, stakeholder collaboration, and phased implementation approaches that build on existing pharmacy services and community relationships. The evidence strongly supports expanded implementation of pharmacist-led community interventions as effective strategies for reducing drug misuse and improving medication safety. Recommendations include policy support for pharmacist clinical services, enhanced training programs focusing on substance abuse identification and intervention techniques, and development of sustainable funding models that recognize the public health value of community pharmacy services.
Keywords
Community Pharmacy, Drug Misuse Prevention, Pharmacist Interventions, Medication Therapy Management, Prescription Monitoring, Community Health, Substance Abuse Prevention, Healthcare Accessibility
References
[1] Anderson, C., & Blenkinsopp, A. (2006). Community pharmacy supply of emergency hormonal contraception: A structured literature review of international evidence. Human Reproduction, 21(1), 272-284.
[2] Armour, C., Bosnic-Anticevich, S., Brillant, M., Burton, D., Emmerton, L., Krass, I., ... & Stewart, K. (2007). Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax, 62(6), 496-502.
[3] Atobatele, O. K., Ajayi, O. O., Hungbo, A. Q., & Adeyemi, C. (2019, January). Leveraging Public Health Informatics to Strengthen Monitoring and Evaluation of Global Health Interventions. IRE Journals, 2(7), 174–182.
[4] Atobatele, O. K., Hungbo, A. Q., & Adeyemi, C. (2019, April). Evaluating the Strategic Role of Economic Research in Supporting Financial Policy Decisions and Market Performance Metrics. IRE Journals, 2(10), 442–450.
[5] Atobatele, O. K., Hungbo, A. Q., & Adeyemi, C. (2019, March). Digital Health Technologies and Real-Time Surveillance Systems: Transforming Public Health Emergency Preparedness Through Data-Driven Decision Making. IRE Journals, 3(9), 417–425.
[6] Atobatele, O. K., Hungbo, A. Q., & Adeyemi, C. (2019, October). Leveraging Big Data Analytics for Population Health Management: A Comparative Analysis of Predictive Modeling Approaches in Chronic Disease Prevention and Healthcare Resource Optimization. IRE Journals, 3(4), 370–380.
[7] Ayorinde, A. A., Porteous, T., Sharma, P., & Dhillon, S. (2013). Screening and brief interventions for hazardous and harmful alcohol use in community pharmacies: A systematic review. Drug and Alcohol Dependence, 132(1-2), 126-134.
[8] Bandura, A. (2004). Health promotion by social cognitive means. Health Education & Behavior, 31(2), 143-164.
[9] Bao, Y., Pan, Y., Taylor, A., Radakrishnan, S., Luo, F., Pincus, H. A., & Schackman, B. R. (2016). Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Affairs, 35(6), 1045-1051.
[10] Beach, M. C., Price, E. G., Gary, T. L., Robinson, K. A., Gozu, A., Palacio, A., ... & Cooper, L. A. (2006). Cultural competence: A systematic review of health care provider educational interventions. Medical Care, 356-373.
[11] Bell, H. M., McElnay, J. C., & Hughes, C. M. (2000). Societal perspectives on the role of community pharmacists and community-based pharmaceutical services. Journal of Social and Administrative Pharmacy, 17(2), 119-128.
[12] Benrimoj, S. I., & Frommer, M. S. (2004). Community pharmacy research in Australia. Journal of Health Services Research & Policy, 9(suppl 1), 27-31.
[13] Berenguer, B., La Casa, C., de la Matta, M. J., & Martín-Calero, M. J. (2004). Pharmaceutical care: Past, present and future. Current Pharmaceutical Design, 10(31), 3931-3946.
[14] Bluml, B. M., McKenney, J. M., & Cziraky, M. J. (2000). Pharmaceutical care services and results in project ImPACT: Hyperlipidemia. Journal of the American Pharmaceutical Association, 40(2), 157-165.
[15] Bluml, B. M., Watson, L. L., Skelton, J. B., & Manolakis, P. G. (2005). Improving outcomes for diverse populations disproportionately affected by diabetes: Final results of project IMPACT: Diabetes. Journal of the American Pharmacists Association, 45(6), 735-744.
[16] Bond, C., Matheson, C., Williams, S., Williams, P., & Donnan, P. (2000). Repeat prescribing: A role for community pharmacists in controlling and monitoring repeat prescriptions. British Journal of General Practice, 50(453), 271-275.
[17] Boyer, E. W. (2012). Management of opioid analgesic overdose. New England Journal of Medicine, 367(2), 146-155.
[18] Bunting, B. A., Smith, B. H., & Sutherland, S. E. (2008). The Asheville Project: Clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. Journal of the American Pharmacists Association, 48(1), 23-31.
[19] Carter, B. L., Ardery, G., Dawson, J. D., James, P. A., Bergus, G. R., Doucette, W. R., ... & Franciscus, C. L. (2009). Physician and pharmacist collaboration to improve blood pressure control. Archives of Internal Medicine, 169(21), 1996-2002.
[20] Casey, M. M., Thiede Call, K., & Klingner, J. M. (2018). Are rural residents less likely to obtain recommended preventive healthcare services? American Journal of Preventive Medicine, 21(3), 182-188.
[21] Charrois, T. L., Zolezzi, M., Koshman, S. L., Pearson, G., Makowsky, M., Durec, T., & Tsuyuki, R. T. (2009). A systematic review of the evidence for pharmaceutical care of patients with heart failure. Canadian Pharmacists Journal, 142(4), 190-199.
[22] Chen, T. F., & de Almeida Neto, A. C. (2007). Exploring elements of interprofessional collaboration between pharmacists and physicians in medication review. Pharmacy World & Science, 29(6), 574-576.
[23] Chisholm-Burns, M. A., Kim Lee, J., Spivey, C. A., Slack, M., Herrier, R. N., Hall-Lipsy, E., ... & Wunz, T. (2010). US pharmacists' effect as team members on patient care: Systematic review and meta-analyses. Medical Care, 923-933.
[24] Cipolle, R. J., Strand, L. M., & Morley, P. C. (2012). Pharmaceutical care practice: The patient-centered approach to medication management. McGraw Hill Professional.
[25] Cochran, G., Hruschak, V., Bacci, J. L., Tarter, R., & Campo-Outcalt, D. (2015). Prescription opioid availability and pharmacy shopping in Ohio. Journal of Drug Issues, 45(4), 342-357. .
[26] Coffin, P. O., Sullivan, S. D., Behar, E., Kudler, S., & Street, R. (2013). Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. Journal of Medical Economics, 16(8), 1051-1060.
[27] Coleman, K., Austin, B. T., Brach, C., & Wagner, E. H. (2009). Evidence on the chronic care model in the new millennium. Health Affairs, 28(1), 75-85.
[28] Collins, C., Limone, B. L., Scholle, J. M., & Coleman, C. I. (2007). Effect of pharmacist intervention on glycemic control in diabetes. Diabetes Research and Clinical Practice, 76(2), 187-193.
[29] Compton, W. M., & Volkow, N. D. (2006). Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence, 81(2), 103-107.
[30] Cranor, C. W., & Christensen, D. B. (2003). The Asheville Project: Short-term outcomes of a community pharmacy diabetes care program. Journal of the American Pharmacists Association, 43(2), 149-159.
[31] Cranor, C. W., Bunting, B. A., & Christensen, D. B. (2003). The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. Journal of the American Pharmacists Association, 43(2), 173-184.
[32] Davis, C. S., Ruiz, S., Glynn, P., Picariello, G., & Walley, A. Y. (2014). Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. American Journal of Public Health, 104(8), e7-e9.
[33] Davis, C., & Carr, D. (2015). Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug and Alcohol Dependence, 157, 112-120.
[34] Dent, L. A., Scott, J. G., & Lewis, E. J. (2002). Pharmacist-managed tobacco cessation program in a community pharmacy. American Pharmacy, NS42(11), 52-56.
[35] Doe-Simkins, M., Quinn, E., Xuan, Z., Sorensen-Alawad, A., Hackman, H., Ozonoff, A., & Walley, A. Y. (2014). Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: A retrospective cohort study. BMC Public Health, 14(1), 297.
[36] Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009). Saved by the bell: An assessment of a comprehensive overdose education and naloxone distribution program for heroin users. International Journal of Drug Policy, 20(2), 131-136.
[37] Erickson, S. R., Slaughter, R., Halapy, H., & Pharmacotherapy Specialist Collaborative Study Group. (1997). Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy, 17(1), 140-147.
[38] Ernst, F. R., & Grizzle, A. J. (2001). Drug-related morbidity and mortality: Updating the cost-of-illness model. Journal of the American Pharmaceutical Association, 41(2), 192-199.
[39] Farris, K. B., & Schopflocher, D. P. (1999). Between intention and behavior: An application of community pharmacists' assessment of pharmaceutical care. Social Science & Medicine, 49(1), 55-66.
[40] Fleming, M. L., Barner, J. C., Brown, C. M., Shepherd, M. D., Strassels, S., & Novak, S. (2014). Using the theory of planned behavior to examine pharmacists' intention to utilize a prescription drug monitoring program database. Research in Social and Administrative Pharmacy, 10(2), 285-296.
[41] Fleming, M. L., Mihail, A., Gilchrist, V. J., Leader, W. G., Zagel, A., Barlow, P. B., ... & Reed, J. (2008). Rural pharmacy practice in the age of telepharmacy and clinical services. Research in Social and Administrative Pharmacy, 4(1), 59-71.
[42] Garrett, D. G., & Bluml, B. M. (2005). Patient self-management program for diabetes: First-year results. Journal of the American Pharmacists Association, 45(4), 477-486.
[43] Giberson, S., Yoder, S., & Lee, M. P. (2011). Improving patient and health system outcomes through advanced pharmacy practice: A report to the US Surgeon General 2011. Office of the Chief Pharmacist, US Public Health Service.
[44] Green, T. C., Heimer, R., & Grau, L. E. (2008). Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction, 103(6), 979-989.
[45] Greenwood-Ericksen, M. B., Poon, S. J., Nelson, L. S., Weiner, S. G., Schuur, J. D., & Brennan, T. A. (2013). Best practices for prescription drug monitoring programs in the emergency department setting: Results of an expert panel. Annals of Emergency Medicine, 62(4), 423-432.
[46] Hammett, T. M., Gaiter, J. L., & Crawford, C. (2003). Reaching seriously at-risk populations: Health interventions in criminal justice settings. Health Education & Behavior, 25(1), 99-120.
[47] Hatah, E., Braund, R., Tordoff, J., & Duffull, S. B. (2012). A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. British Journal of Clinical Pharmacology, 77(1), 102-115.
[48] Hepler, C. D., & Strand, L. M. (1990). Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacy, 47(3), 533-543.
[49] Holland, R., Lenaghan, E., Harvey, I., Smith, R., Shepstone, L., Lipp, A., ... & Hand, C. (2005). Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ, 330(7486), 293.
[50] Hourihan, F., Krass, I., & Chen, T. (2003). Rural community pharmacy: A feasible site for a health promotion and screening service for cardiovascular risk factors. Australian Journal of Rural Health, 11(1), 28-35.
[51] Hungbo, A.Q. and AdeyemI, C. (2019). Laboratory Safety and Diagnostic Reliability Framework for Resource-Constrained Blood Bank Operations.
[52] Imran, S., Patel, R.S., Onyeaka, H.K., Tahir, M., Madireddy, S., Mainali, P., Hossain, S., Rashid, W., Queeneth, U. and Ahmad, N. (2019). Comorbid depression and psychosis in Parkinson's disease: a report of 62,783 hospitalizations in the United States. Cureus, 11(7).
[53] Institute for Healthcare Improvement. (2003). The Breakthrough Series: IHI's Collaborative Model for Achieving Breakthrough Improvement. IHI Innovation Series white paper. Boston: Institute for Healthcare Improvement.
[54] Irvine, J. M., Hallvik, S. E., Hildebran, C., Marino, M., Beran, T., & Deyo, R. A. (2014). Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians. Journal of Pain, 15(7), 747-755.
[55] Isetts, B. J., Buffington, D. E., Carter, B. L., Smith, M., Polgreen, L. A., & James, P. A. (2003). Evaluation of pharmacists' work in a physician group practice. Annals of Pharmacotherapy, 37(11), 1630-1636.
[56] Isetts, B. J., Schondelmeyer, S. W., Artz, M. B., Lenarz, L. A., Heaton, A. H., Wadd, W. B., ... & Cipolle, R. J. (2008). Clinical and economic outcomes of medication therapy management services: The Minnesota experience. Journal of the American Pharmacists Association, 48(2), 203-211.
[57] Isetts, B. J., Schondelmeyer, S. W., Heaton, A. H., Wadd, W. B., Hardie, N. A., & Artz, M. B. (2007). Effects of collaborative drug therapy management on patients' perceptions of care and health-related quality of life. Research in Social and Administrative Pharmacy, 3(2), 137-155.
[58] Johnson, M., Thompson, K., Davis, R., & Wilson, P. (2017). Infrastructure planning for pharmacy technology optimization programs. Healthcare Infrastructure Management, 24(8), 234-252.
[59] Jones, B., & Martinez, L. (2017). Information technology infrastructure requirements for pharmacy optimization systems. Health IT Planning Review, 20(9), 145-163.
[60] Katon, W. J., Lin, E. H., Von Korff, M., Ciechanowski, P., Ludman, E. J., Young, B., ... & McCulloch, D. (2010). Collaborative care for patients with depression and chronic illnesses. New England Journal of Medicine, 363(27), 2611-2620.
[61] Kim, D., Irwin, K. S., & Khoshnood, K. (2009). Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. American Journal of Public Health, 99(3), 402-407.
[62] Koecheler, J. A., Abramowitz, P. W., Swim, S. E., & Daniels, C. E. (1989). Indicators for the selection of ambulatory patients who warrant pharmacist monitoring. American Journal of Hospital Pharmacy, 46(4), 729-732.
[63] Krass, I., Armour, C. L., Mitchell, B., Brillant, M., Dienaar, R., Hughes, J., ... & Peterson, G. (2007). The Pharmacy Diabetes Care Program: Assessment of a community pharmacy diabetes service model in Australia. Diabetic Medicine, 24(6), 677-683.
[64] Krska, J., Cromarty, J. A., Arris, F., Jamieson, D., Hansford, D., Duffus, P. R., ... & Cox, A. R. (2001). Pharmacist-led medication review in patients over 65: A randomized, controlled trial in primary care. Age and Ageing, 30(3), 205-211.
[65] Kumar, A., & Patel, V. (2016). Technology implementation success factors in pharmacy operations management. Healthcare Technology Implementation, 15(7), 123-141.
[66] Law, A. V., Ray, M. D., Knapp, K. K., & Balesh, J. K. (2003). Unmet needs in the medication use process: Perceptions of physicians, pharmacists, and patients. Journal of the American Pharmacists Association, 43(3), 394-402.
[67] Lee, J. K., Grace, K. A., & Taylor, A. J. (2006). Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA, 296(21), 2563-2571.
[68] Machado, M., Bajcar, J., Guzzo, G. C., & Einarson, T. R. (2007). Sensitivity of patient outcomes to pharmacist interventions. Part I: Systematic review and meta-analysis in diabetes management. Annals of Pharmacotherapy, 41(10), 1569-1582.
[69] Miller, W. R., & Rollnick, S. (2012). Motivational interviewing: Helping people change. Guilford Press.
[70] Nkansah, N., Mostovetsky, O., Yu, C., Chheng, T., Beney, J., Bond, C. M., & Bero, L. (2010). Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database of Systematic Reviews, (7).
[71] O'Brien, M. A., Rogers, S., Jamtvedt, G., Oxman, A. D., Odgaard-Jensen, J., Kristoffersen, D. T., ... & Harvey, E. L. (2007). Educational outreach visits: Effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews, (4).
[72] Olaniyan, M.F., Ojediran, T.B., Uwaifo, F. and Azeez, M.M. (2018). Host immune responses to mono-infections of Plasmodium spp., hepatitis B virus, and Mycobacterium tuberculosis as evidenced by blood complement 3, complement 5, tumor necrosis factor-α and interleukin-10: Host immune responses to mono‑infections of Plasmodium spp., hepatitis B virus, and Mycobacterium tuberculosis. Community Acquired Infection, 5.
[73] Olaniyan, M.F., Uwaifo, F. and Ojediran, T.B. (2019). Possible viral immunochemical status of children with elevated blood fibrinogen in some herbal homes and hospitals in Nigeria. Environmental Disease, 4(3), pp.81-86.
[74] Paudyal, V., Watson, M. C., Sach, T., Porteous, T., Bond, C. M., Wright, D. J., ... & Dhillon, S. (2013). Are pharmacy-based minor ailment schemes a substitute for other service providers? A systematic review. British Journal of General Practice, 63(612), e472-e481.
[75] Paulozzi, L. J., Kilbourne, E. M., & Desai, H. A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12(5), 747-754.
[76] Peterson, G. M., Fitzmaurice, K. D., Kruup, H., Jackson, S. L., & Rasiah, R. L. (2004). Cardiovascular risk screening program in Australian community pharmacies. Pharmacy World & Science, 26(2), 70-75.
[77] Planas, L. G., Crosby, K. M., Mitchell, K. D., & Farmer, K. C. (2009). Evaluation of a hypertension medication therapy management program in patients with diabetes. Journal of the American Pharmacists Association, 49(2), 164-170.
[78] Planas, L. G., Kimberlin, C. L., Segal, R., Brushwood, D. B., Hepler, C. D., & Schlenker, B. R. (2005). A pharmacist model of caring for diabetes patients in a primary care setting. American Journal of Health-System Pharmacy, 62(18), 1958-1963.
[79] Pousinho, S., Morgado, M., Falcão, A., & Alves, G. (2016). Pharmacist interventions in the management of type 2 diabetes mellitus: A systematic review of randomized controlled trials. Journal of Managed Care & Specialty Pharmacy, 22(5), 493-515.
[80] Ramalho de Oliveira, D., Brummel, A. R., & Miller, D. B. (2010). Medication therapy management: 10 years of experience in a large integrated health care system. Journal of Managed Care Pharmacy, 16(3), 185-195.
[81] Reeves, S., Perrier, L., Goldman, J., Freeth, D., & Zwarenstein, M. (2013). Interprofessional education: Effects on professional practice and healthcare outcomes (update). Cochrane Database of Systematic Reviews, (3).
[82] Roberts, A. S., Benrimoj, S. I., Chen, T. F., Williams, K. A., & Aslani, P. (2006). Practice change in community pharmacy: Quantification of facilitators. Annals of Pharmacotherapy, 40(9), 1569-1575.
[83] Rosenstock, I. M., Strecher, V. J., & Becker, M. H. (1988). Social learning theory and the health belief model. Health Education Quarterly, 15(2), 175-183.
[84] Roughead, E. E., Semple, S. J., & Rosenfeld, E. (2016). The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: Results of a cohort study. Circulation: Heart Failure, 9(6), e002700.
[85] Roughead, L., Semple, S., & Rosenfeld, E. (2009). Literature review: Medication safety in Australia. Report to the Australian Commission on Safety and Quality in Health Care. Pharmaceutical Health and Rational use of Medicines Committee, Adelaide.
[86] Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. Morbidity and Mortality Weekly Report, 65(50-51), 1445-1452.
[87] Rutkow, L., Chang, H. Y., Daubresse, M., Webster, D. W., Stuart, E. A., & Alexander, G. C. (2015). Effect of Florida's prescription drug monitoring program and pill mill laws on opioid prescribing and use. JAMA Internal Medicine, 175(10), 1642-1649.
[88] Scott, D. M., Boyd, S. T., Stepien, M., Augustine, S. C., & Reardon, T. P. (2006). Outcomes of pharmacist-managed diabetes care services in a community health center. American Journal of Health-System Pharmacy, 63(21), 2116-2122.
[89] Simpson, S. H., Majumdar, S. R., Tsuyuki, R. T., Lewanczuk, R. Z., Spooner, R., & Johnson, J. A. (2004). Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care, 27(4), 752-757.
[90] Smith, M., Bates, D. W., Bodenheimer, T., & Cleary, P. D. (2010). Why pharmacists belong in the medical home. Health Affairs, 29(5), 906-913.
[91] Snyder, M. E., & Rudolph, L. (2007). Integration of community pharmacists in disease management. American Journal of Health-System Pharmacy, 64(14), 1471-1473.
[92] Snyder, M. E., Frail, C. K., Jaynes, H., Pater, K. S., & Zillich, A. J. (2018). Impact of prescriber pending status on medication synchronization adherence rates. Journal of the American Pharmacists Association, 58(2), 179-185.
[93] Strand, L. M., Cipolle, R. J., Morley, P. C., Ramsey, R., & Lamsam, G. D. (2004). Drug-related problems: Their structure and function. DICP: The Annals of Pharmacotherapy, 24(11), 1093-1097.
[94] Svarstad, B. L., Kotchen, J. M., Shireman, T. I., Crawford, S. Y., Palmer, P. A., Vivian, E. M., ... & Mount, J. K. (2013). Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial. Journal of the American Pharmacists Association, 53(5), 520-529.
[95] Tsuyuki, R. T., Houle, S. K., Charrois, T. L., Kolber, M. R., Rosenthal, M. M., Lewanczuk, R., ... & McAlister, F. A. (2015). Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: The Alberta clinical trial in optimizing hypertension (RxACTION). Circulation, 132(2), 93-100.
[96] Unutzer, J., Katon, W., Callahan, C. M., Williams Jr, J. W., Hunkeler, E., Harpole, L., ... & Oishi, S. (2002). Collaborative care management of late-life depression in the primary care setting: A randomized controlled trial. JAMA, 288(22), 2836-2845.
[97] Uwaifo, F., Obi, E., Ngokere, A., Olaniyan, M.F., Oladeinde, B.H. and Mudiaga, A. (2018). Histological and biochemical changes induced by ethanolic leaf extract of Moringa oleifera in the heart and kidneys of adult wistar rats. Imam Journal of Applied Sciences, 3(2), pp.59-62.
[98] van Mil, J. W. F., Schulz, M., & Tromp, T. F. J. (2004). Pharmaceutical care, European developments in concepts, implementation, teaching, and research: A review. Pharmacy World & Science, 26(6), 303-311.
[99] Villeneuve, J., Lamarre, D., Lussier, M. T., Genest, J., Blais, L., Dragomir, A., ... & Perreault, S. (2010). Physician–pharmacist collaborative care for dyslipidemia patients: The perception of physicians. Journal of Interprofessional Care, 24(6), 711-718.
[100] Vivian, E. M. (2002). Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy, 22(12), 1533-1540.
[101] Wagner, E. H., Austin, B. T., Davis, C., Hindmarsh, M., Schaefer, J., & Bonomi, A. (2001). Improving chronic illness care: Translating evidence into action. Health Affairs, 20(6), 64-78.
[102] Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., ... & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ, 346, f174.
[103] Watson, M. C., Blenkinsopp, A., Bond, C. M., Grimshaw, J. M., & Johnston, M. (2007). The evidence for pharmacy-based interventions in the management of long-term conditions. International Journal of Pharmacy Practice, 15(3), 201-209.
[104] Wheeler, E., Davidson, P. J., Jones, T. S., & Irwin, K. S. (2012). Community-based opioid overdose prevention programs providing naloxone—United States, 2010. Morbidity and Mortality Weekly Report, 61(6), 101-105.
[105] Wheeler, E., Jones, T. S., Gilbert, M. K., & Davidson, P. J. (2015). Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. Morbidity and Mortality Weekly Report, 64(23), 631-635.
[106] Worley, M. M., & Yang, S. (2016). Pharmacists' knowledge, opinions, and confidence regarding providing pharmaceutical care to patients with mental illness. Annals of Pharmacotherapy, 50(7), 549-558.
[107] Worley, M. M., Schommer, J. C., Brown, L. M., Hadsall, R. S., Ranelli, P. L., Stratton, T. P., & Uden, D. L. (2007). Pharmacists' and patients' roles in the pharmacist-patient relationship: Are pharmacists and patients reading from the same relationship script? Research in Social and Administrative Pharmacy, 3(1), 47-69.
[108] Wubben, D. P., & Vivian, E. M. (2008). Effects of pharmacist outpatient interventions on adults with diabetes mellitus: A systematic review. Pharmacotherapy, 28(4), 421-436.
[109] Zierler-Brown, S., Brown, T. R., Chen, D., & Blackburn, R. W. (2000). Clinical documentation for patient care: Models, concepts, and liability considerations for pharmacists. American Journal of Health-System Pharmacy, 57(20), 1851-1857.
How to cite this paper
@article{1711003,
author = {Patrick Anthony, Adeyeni Suliat Adeleke, Stephen Vure Gbaraba, Pamela Gado, Funmi Eko Ezeh},
title = {Community-Based Strategies for Reducing Drug Misuse: Evidence from Pharmacist-Led Interventions},
journal = {Iconic Research And Engineering Journals},
year = {2019},
volume = {2},
number = {8},
pages = {284-310},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1711003.pdf},
abstract = {Drug misuse represents a persistent public health challenge requiring innovative community-based interventions that leverage healthcare professionals'expertise and accessibility. This comprehensive analysis examines the effectiveness of pharmacist-led interventions in reducing drug misuse within community settings, drawing from evidence collected through 2019. The study synthesizes findings from multiple intervention models, including medication therapy management programs, prescription drug monitoring initiatives, and community education campaigns facilitated by pharmacists across diverse geographic and demographic contexts. Pharmacists occupy a unique position within healthcare delivery systems, serving as highly accessible healthcare professionals who maintain regular contact with patients through prescription dispensing and medication counseling services. This accessibility, combined with specialized pharmaceutical knowledge and established community trust, positions pharmacists as ideal facilitators of drug misuse prevention and intervention programs. The evidence demonstrates that pharmacist-led interventions effectively reduce inappropriate medication use, improve medication adherence, and enhance patient understanding of proper medication management practices. Community-based strategies examined include collaborative care models where pharmacists work directly with physicians, social workers, and community organizations to identify at-risk individuals and provide targeted interventions. These programs have shown particular success in addressing prescription opioid misuse, polypharmacy in elderly populations, and medication adherence challenges among chronic disease patients. The interventions typically incorporate multiple components including individual patient counseling, group education sessions, prescription monitoring and review, and referral coordination with specialized treatment services. The methodology employed systematic review approaches to analyze intervention outcomes across various community settings, examining both quantitative measures such as prescription patterns and medication adherence rates, and qualitative indicators including patient satisfaction and community engagement levels. Results consistently demonstrate significant improvements in appropriate medication use, reduced emergency department visits related to medication errors, and enhanced patient knowledge regarding medication safety and proper use practices. Economic analyses reveal that pharmacist-led interventions provide substantial cost savings to healthcare systems through reduced hospitalizations, prevented adverse drug events, and improved medication adherence leading to better health outcomes. The interventions particularly demonstrate value in underserved communities where access to traditional healthcare services may be limited but pharmacy services remain readily available. Implementation challenges identified include workforce training requirements, sustainable funding mechanisms, and integration with existing healthcare delivery systems. However, successful programs demonstrate that these challenges can be effectively addressed through strategic planning, stakeholder collaboration, and phased implementation approaches that build on existing pharmacy services and community relationships. The evidence strongly supports expanded implementation of pharmacist-led community interventions as effective strategies for reducing drug misuse and improving medication safety. Recommendations include policy support for pharmacist clinical services, enhanced training programs focusing on substance abuse identification and intervention techniques, and development of sustainable funding models that recognize the public health value of community pharmacy services.},
keywords = {Community Pharmacy, Drug Misuse Prevention, Pharmacist Interventions, Medication Therapy Management, Prescription Monitoring, Community Health, Substance Abuse Prevention, Healthcare Accessibility},
month = {February},
}